Third Rock Ventures V, L.P. sold $11M of RAPP
owner at Rapport Therapeutics, Inc.. 276,513 shares at an average of $40.12, traded May 7, 2026, filed May 11, 2026.
Score components
- +12Role10% owner
- +25Trade size$11.1M at market
- 0Share of holdings soldSold 4.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-217092, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 7, 2026 | SOpen-market sale Common Stock10b5-1 | -271,495 | $40.12 | $11M | 6,437,733 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -5,018 | $40.31 | $202k | 6,432,715 | May 11, 2026 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 37Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $938k 18,921 shares | -4% | |
| 33Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $2.5M 50,160 shares | -20% | |
| 3Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $20k 404 shares | -0% | |
| 38Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $2.4M 51,499 shares | -10% | |
| 15Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $93k 2,210 shares | -0% | |
| 28Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $328k 8,210 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.